JP2009518299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518299A5 JP2009518299A5 JP2008543484A JP2008543484A JP2009518299A5 JP 2009518299 A5 JP2009518299 A5 JP 2009518299A5 JP 2008543484 A JP2008543484 A JP 2008543484A JP 2008543484 A JP2008543484 A JP 2008543484A JP 2009518299 A5 JP2009518299 A5 JP 2009518299A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- composition
- polypeptide
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims 124
- 229940024606 amino acid Drugs 0.000 claims 124
- 150000001413 amino acids Chemical class 0.000 claims 121
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 118
- 239000000203 mixture Substances 0.000 claims 107
- 108090000765 processed proteins & peptides Proteins 0.000 claims 93
- 229920001184 polypeptide Polymers 0.000 claims 75
- 102000004196 processed proteins & peptides Human genes 0.000 claims 75
- 239000012634 fragment Substances 0.000 claims 43
- 239000005557 antagonist Substances 0.000 claims 25
- 108091033319 polynucleotide Proteins 0.000 claims 17
- 239000002157 polynucleotide Substances 0.000 claims 17
- 102000040430 polynucleotide Human genes 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 239000013598 vector Substances 0.000 claims 15
- 230000006378 damage Effects 0.000 claims 11
- 208000027418 Wounds and injury Diseases 0.000 claims 10
- 208000014674 injury Diseases 0.000 claims 10
- 239000011230 binding agent Substances 0.000 claims 9
- 201000006417 multiple sclerosis Diseases 0.000 claims 9
- 210000004248 oligodendroglia Anatomy 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 239000004055 small Interfering RNA Substances 0.000 claims 7
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 102000001189 Cyclic Peptides Human genes 0.000 claims 5
- 108010069514 Cyclic Peptides Proteins 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims 4
- 206010047631 Vitamin E deficiency Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- 230000001086 cytosolic effect Effects 0.000 claims 4
- 201000002491 encephalomyelitis Diseases 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- -1 SEQ ID NO: 2 Amino acids Chemical class 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 229920001515 polyalkylene glycol Polymers 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 208000011403 Alexander disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006373 Bell palsy Diseases 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 206010067601 Dysmyelination Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims 2
- 206010073696 Wallerian degeneration Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000036546 leukodystrophy Diseases 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000009174 transverse myelitis Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 230000008734 wallerian degeneration Effects 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 241000710778 Pestivirus Species 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000023105 myelination Effects 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74144105P | 2005-12-02 | 2005-12-02 | |
| US60/741,441 | 2005-12-02 | ||
| PCT/US2006/045993 WO2007064882A2 (en) | 2005-12-02 | 2006-12-01 | Treatment of conditions involving demyelination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013045890A Division JP2013136624A (ja) | 2005-12-02 | 2013-03-07 | 脱髄の関与する状態の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009518299A JP2009518299A (ja) | 2009-05-07 |
| JP2009518299A5 true JP2009518299A5 (https=) | 2011-01-27 |
| JP5312039B2 JP5312039B2 (ja) | 2013-10-09 |
Family
ID=38092820
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008543484A Expired - Fee Related JP5312039B2 (ja) | 2005-12-02 | 2006-12-01 | 脱髄の関与する状態の処置 |
| JP2013045890A Withdrawn JP2013136624A (ja) | 2005-12-02 | 2013-03-07 | 脱髄の関与する状態の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013045890A Withdrawn JP2013136624A (ja) | 2005-12-02 | 2013-03-07 | 脱髄の関与する状態の処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090175872A1 (https=) |
| EP (2) | EP2543384A3 (https=) |
| JP (2) | JP5312039B2 (https=) |
| AU (1) | AU2006320479B2 (https=) |
| CA (1) | CA2631181A1 (https=) |
| NZ (2) | NZ598421A (https=) |
| WO (1) | WO2007064882A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004085648A2 (en) | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| PT1776136E (pt) | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Tratamento de estados que envolvem desmielinização |
| SI1904104T1 (sl) * | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| KR20080080109A (ko) * | 2005-11-04 | 2008-09-02 | 바이오겐 아이덱 엠에이 인코포레이티드 | 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법 |
| JP2009544703A (ja) | 2006-07-24 | 2009-12-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| WO2009048605A1 (en) * | 2007-10-11 | 2009-04-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
| CA2702630C (en) * | 2007-11-08 | 2017-11-21 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| US20110118340A1 (en) * | 2008-02-08 | 2011-05-19 | Muthiah Manoharan | Delivery of rnai constructs to oligodendrocytes |
| DK2982695T3 (da) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| CN104470541A (zh) | 2012-05-14 | 2015-03-25 | 比奥根艾迪克Ma公司 | 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂 |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用 |
| AU2016270373A1 (en) | 2015-06-05 | 2018-01-04 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| KR102014056B1 (ko) * | 2017-04-18 | 2019-08-27 | 앱클론(주) | 단백질의 순도 및 항원에 대한 친화성이 향상된 폴리펩티드, 이의 항체 또는 항원 결합 단편과의 복합체, 및 이들의 제조방법 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773319A (en) | 1971-12-16 | 1973-11-20 | Fabcor Ind Inc | Corrugated sheet inverting machine |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech, Inc., South San Francisco, Calif. | Her2 extrazellulare domäne |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5219837A (en) | 1990-06-21 | 1993-06-15 | Trustees Of The University Of Pennsylvania | Method of stimulating myelination of cells |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| DE669986T1 (de) | 1992-11-13 | 1996-10-10 | Idec Pharma Corp | Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung. |
| WO1995014930A1 (en) | 1993-11-23 | 1995-06-01 | Genentech, Inc. | Kinase receptor activation assay |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| DE4415539C2 (de) | 1994-05-03 | 1996-08-01 | Osama Dr Dr Med Omer | Pflanzen mit virustatischer und antiviraler Wirkung |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6280964B1 (en) | 1995-04-14 | 2001-08-28 | The Regents Of The University Of California | Binding sites for phosphotyrosine binding domains |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| CA2245835A1 (en) | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| WO1998002540A1 (en) * | 1996-07-12 | 1998-01-22 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| ES2242997T3 (es) | 1997-03-14 | 2005-11-16 | Biogen Idec Inc. | Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo. |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| WO1999004705A1 (en) | 1997-07-25 | 1999-02-04 | Tsui Ban C H | Devices, systems and methods for determining proper placement of epidural catheters |
| WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| WO2001001748A2 (en) | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Peptide compounds that bind her2 |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| EP1340088B1 (en) | 2000-11-17 | 2007-01-17 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| BR0206985A (pt) | 2001-01-29 | 2005-04-19 | Idec Pharma Corp | Anticorpos modificados e métodos de uso |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| AU2002365258A1 (en) | 2001-10-12 | 2003-09-02 | University Of Vermont And State Agricultural College | Binding peptides specific for the extracellular domain of erbb2 and uses therefor |
| US7077522B2 (en) | 2002-05-03 | 2006-07-18 | University Of Rochester | Sharpness metric for vision quality |
| US6794785B2 (en) | 2002-06-26 | 2004-09-21 | Denso Corporation | Alternator for vehicles |
| WO2004085648A2 (en) * | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| JP4969440B2 (ja) | 2004-04-08 | 2012-07-04 | デビッド， ビー． エイガス， | 疼痛治療のためのＥｒｂＢアンタゴニスト |
| PT1776136E (pt) * | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Tratamento de estados que envolvem desmielinização |
| US8819140B2 (en) | 2004-07-09 | 2014-08-26 | Qualcomm Incorporated | System and method for enabling the establishment and use of a personal network |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| KR20080080109A (ko) * | 2005-11-04 | 2008-09-02 | 바이오겐 아이덱 엠에이 인코포레이티드 | 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법 |
| JP2009544703A (ja) * | 2006-07-24 | 2009-12-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 |
| ATE502960T1 (de) * | 2006-11-17 | 2011-04-15 | Novartis Ag | Lingo bindende moleküle und pharmazeutische verwendung davon |
| US8128926B2 (en) * | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| WO2009048605A1 (en) * | 2007-10-11 | 2009-04-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
| DK2982695T3 (da) * | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
-
2006
- 2006-12-01 CA CA002631181A patent/CA2631181A1/en not_active Abandoned
- 2006-12-01 US US12/095,857 patent/US20090175872A1/en not_active Abandoned
- 2006-12-01 NZ NZ598421A patent/NZ598421A/xx not_active IP Right Cessation
- 2006-12-01 EP EP12156990.9A patent/EP2543384A3/en not_active Withdrawn
- 2006-12-01 WO PCT/US2006/045993 patent/WO2007064882A2/en not_active Ceased
- 2006-12-01 JP JP2008543484A patent/JP5312039B2/ja not_active Expired - Fee Related
- 2006-12-01 NZ NZ569428A patent/NZ569428A/xx not_active IP Right Cessation
- 2006-12-01 EP EP06838776.0A patent/EP1965827B1/en active Active
- 2006-12-01 AU AU2006320479A patent/AU2006320479B2/en not_active Ceased
-
2013
- 2013-03-07 JP JP2013045890A patent/JP2013136624A/ja not_active Withdrawn
-
2015
- 2015-06-09 US US14/734,144 patent/US20160002329A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518299A5 (https=) | ||
| AU2007215275B2 (en) | Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS | |
| AU2024287134A1 (en) | Multi-chain chimeric polypeptides and uses there | |
| US9260493B2 (en) | Transducible delivery of nucleic acids using modified dsRNA binding domains | |
| JP2008504297A5 (https=) | ||
| US20160031991A1 (en) | Targeting vaccines for veterinary use | |
| JP2009538282A5 (https=) | ||
| CN111892661A (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| JP2009517340A5 (https=) | ||
| EP4151659A1 (en) | Biological macromolecular target-specific complement inhibitor, preparation method therefor, and application thereof | |
| IL209595A (en) | Isolated nucleic acid, expression vector and host cell containing it, isolated polypeptide encoded by it and chimeric polypeptide containing it, process for preparation, oligopeptide hhipl l2 mimics loop, preparations containing it and methods for its production | |
| AU2024201112A1 (en) | Composition comprising VGLL1 peptide for treatment of cancer | |
| CA2981191C (en) | Compositions comprising pregnancy specific glycoproteins and methods of use thereof | |
| CA3150731A1 (en) | Anti-viral compositions and methods of making and using | |
| US8470971B2 (en) | Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient | |
| US12528853B2 (en) | T-cell receptor for treating fibrolamellar hepatocellular carcinoma | |
| CN101421301A (zh) | 通过dsRNA结合域与PTD/CPPS的融合物转导运输siRNA | |
| CN108250277B (zh) | 微小rna31前体编码多肽的截短体在制备免疫调节药物中的应用 | |
| US20250195573A1 (en) | Genetically engineered t-cell co-receptors and methods of use thereof | |
| CN101195657B (zh) | 一个i型细胞因子受体样分子及其编码基因的应用 | |
| KR102957751B1 (ko) | Mage a4 t 세포 수용체 | |
| HK40084879A (en) | Biological macromolecular target-specific complement inhibitor, preparation method therefor, and application thereof | |
| NZ745831A (en) | Optimized factor viii genes | |
| NZ745831B2 (en) | Optimized factor viii genes | |
| ITMI950264A1 (it) | Sintesi tramite dna ricombinante di una proteina chimerica tra la tossina difterica e il fattore neurotrofico ciliare umano capace |